Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04693351 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
A Phase 3 study of Obsessive - Compulsive Disorder, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 589
- Enrollment target
- 20
- Study locations
NCT04693351 is a Phase 3 study of Obsessive - Compulsive Disorder that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 589 participants, below the 2,058-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT04693351, a Phase 3 study of Obsessive - Compulsive Disorder, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 589 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Troriluzole
Study Locations (20)
Florida
- Topaz Clinical Research - Apopka
- CNS Research of Coral Springs - Coral Springs
- Gulfcoast Clinical Research Center - Fort Myers
- University of Florida Department of Psychiatry - Gainesville
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Med-Care Research - Miami
- Ezy Medical Research, Co. - Miami
- Advanced Research for Health Improvement - Naples
- Harmony Clinical Research - North Miami Beach
California
- ProScience Research Group - Culver City
- Kaizen Brain Center - La Jolla
- Om Research LLC - Lancaster
- CalNeuro Research Group - Los Angeles
- Lumos Clinical Research Center, LLC - San Jose
- Velocity Clinical Research - Santa Ana
- California Neuroscience Research Medical Group, Inc. - Sherman Oaks
- Pacific Clinical Research Medical Group - Upland
Arizona
- Alea Research - Phoenix
Colorado
- Mountain View Clinical Research - Denver
Connecticut
- Comprehensive Psychiatric Care - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2025-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04693351
The ClinicalTrials.gov registry entry for NCT04693351 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,058-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (71% lower). The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04693351 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04693351 about?
NCT04693351 is a clinical study titled "Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder". The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
What is the current status of trial NCT04693351?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2021-01-29. Estimated completion is 2025-04-29.
What conditions does trial NCT04693351 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.
What interventions are being tested in trial NCT04693351?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT04693351?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04693351 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Obsessive-Compulsive Disorder (OCD) in Children
COMPLETED · Phase 3
-
Treatment of Obsessive Compulsive Disorder in Children
COMPLETED · Phase 3
-
Family Based Treatment of Early Childhood Obsessive Compulsive Disorder
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder
COMPLETED · Phase 3
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.